ABBV-295
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
AbbVie · Phase 1 · Active, not recruiting · Enrollment 80
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.